MICHAEL R MIGDEN to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Programmed Cell Death 1 Receptor.
Connection Strength
1.159
-
Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 01; 45(1):1-16.
Score: 0.401
-
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 07 26; 379(4):341-351.
Score: 0.385
-
PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis. Australas J Dermatol. 2022 Feb; 63(1):36-42.
Score: 0.122
-
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):848-857.
Score: 0.118
-
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):947-951.
Score: 0.105
-
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 06; 8(1).
Score: 0.028